VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

IPO Year: 2006

Exchange: NASDAQ

Website: vandapharma.com

Recent Analyst Ratings for Vanda Pharmaceuticals Inc.

Date	Price Target	Rating	Analyst
10/31/2024	$18.00	Buy	H.C. Wainwright
7/11/2024	$11.00	Overweight	Cantor Fitzgerald
2/25/2022	$24.00 → $12.00	Buy → Hold	Jefferies

See more ratings

Vanda Pharmaceuticals Inc.

Recent Analyst Ratings for Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.

Recent Analyst Ratings for Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. SEC Filings

SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form SCHEDULE 13G filed by Vanda Pharmaceuticals Inc.

SEC Form 144 filed by Vanda Pharmaceuticals Inc.

SEC Form S-8 filed by Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc.

SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. FDA approvals

FDA Approval for PONVORY issued to VANDA PHARMS INC

FDA Approval for PONVORY issued to VANDA PHARMS INC

FDA Approval for FANAPT issued to VANDA PHARMS INC

Vanda Pharmaceuticals Inc. Insider Purchases

President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $50,150 worth of shares (10,000 units at $5.01), increasing direct ownership by 0.44% to 2,295,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $50,200 worth of shares (10,000 units at $5.02), increasing direct ownership by 0.44% to 2,285,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos covered exercise/tax liability with 95,999 shares and bought $47,050 worth of shares (10,000 units at $4.71), decreasing direct ownership by 4% to 2,275,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $47,600 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,361,730 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $47,600 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,351,730 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $47,650 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,341,730 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $44,640 worth of shares (10,000 units at $4.46), increasing direct ownership by 0.43% to 2,331,730 units (SEC Form 4)

Vanda Pharmaceuticals Inc. Press Releases

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Vanda Pharmaceuticals Inc. Analyst Ratings

H.C. Wainwright initiated coverage on Vanda Pharma with a new price target

Cantor Fitzgerald initiated coverage on Vanda Pharma with a new price target

Vanda Pharmaceuticals downgraded by Jefferies with a new price target

B of A Securities initiated coverage on Vanda Pharmaceuticals with a new price target

Citigroup reiterated coverage on Vanda Pharmaceuticals with a new price target

Vanda Pharmaceuticals Inc. Leadership Updates

Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

Vanda Pharmaceuticals Inc. Financials

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results

Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024

Vanda Pharmaceuticals Inc. Large Ownership Changes

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G filed by Vanda Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

Vanda Pharmaceuticals Inc. Insider Trading

President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

Director Mitchell Stephen Ray sold $32,130 worth of shares (7,000 units at $4.59), decreasing direct ownership by 7% to 97,082 units (SEC Form 4)

Director Mitchell Stephen Ray was granted 59,225 shares, increasing direct ownership by 132% to 104,082 units (SEC Form 4)

Director Chrousos Phaedra was granted 59,225 shares, increasing direct ownership by 92% to 123,350 units (SEC Form 4)

Director Dugan Richard W was granted 59,225 shares, increasing direct ownership by 50% to 177,454 units (SEC Form 4)

Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4)

Director Ward Anne Sempowski was granted 59,225 shares, increasing direct ownership by 99% to 119,067 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4)